The intersection of generic pharmaceutical patents and FDA law represents one of the most intricate yet impactful domains in healthcare […]
Generic Pharmaceutical Patent and FDA Law: Navigating the Complex Landscape Read Post »
This article was originally published by Philippe Lahorte in World Patent Information Volume 54, Supplement, September 2018, Pages S18-S22 Under
Inside the mind of an EPO examiner Read Post »
We thought you might be interested in some of the great reviews we’re getting over at software review site G2Crowd.
See What Others are Saying About DrugPatentWatch Read Post »
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics: What They Are and Why They’re Profitable Read Post »
The landscape of pharmaceutical patent litigation has undergone significant transformation in recent years, with Abbreviated New Drug Application (ANDA) filings
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
How Pharmaceutical Life Cycle Management Strategies Are Evolving Read Post »
Get fresh news and insights, drug patent expirations & more…
